Cytori Therapeutics Inc(NASDAQ:CYTX) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 23, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $1.466M. Analysts estimated a revenue of $2.690M. The revenues were -45.5% below the estimates. Earnings per share were $-0.24. The reported EPS was below estimates by -4.35%. Analysts had estimated an EPS of $-0.23.
Cytori Therapeutics Inc (CYTX) made into the market gainers list on Fridays trading session with the shares advancing 0.61% or 0.01 points. Due to strong positive momentum, the stock ended at $1.65, which is also near the day’s high of $1.65. The stock began the session at $1.61 and the volume stood at 94,491 shares. The 52-week high of the shares is $5.437472 and the 52 week low is $1.36. The company has a current market capitalization of $35 M and it has 2,15,07,903 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Aug 11, 2016, John David Harris (VP and GM Cell Therapy) purchased 2,500 shares at $2.03 per share price.Also, On Jun 15, 2016, David Rickey (director) purchased 5,000 shares at $2.10 per share price.On Jun 15, 2016, Gail K Naughton (director) purchased 1,000 shares at $2.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Cytori Therapeutics Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product Cytori Cell Therapy for patients with scleroderma hand dysfunction orthopedic disorders cardiovascular disease urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe Japan and other regions. The Company offers ECCO-50 a cure for knee osteoarthritis which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50 a cure for urinary incontinence which is in Phase II/III of development. The Company is also developing DCCT-10 a cure for cutaneous thermal injury.